A method for the treatment of causalgia after amputation of the lower extremities

 

(57) Abstract:

The invention relates to medicine, surgery, and can be used for the treatment of causalgia after amputation of the lower extremities. Injected into the femoral artery of 0.1-0.15% solution of hydrogen peroxide in a volume of 200.0 ml of This invention promotes adequate analgesia and reduce the invasiveness and morbidity methods of pain relief.

The invention relates to the field of medicine and is intended for the treatment of causalgia.

There is a method of treatment of causalgia (H. Hodos, Nervous diseases: Guide for physicians. - 3rd ed., Corr. and extra - So: Medicine, 1981, S. 298-299), which is that used neurosis, neurotomy and neurectomy as the stages of surgical treatment of this disease.

The disadvantages of this method are primarily: high invasiveness and trauma. In addition, quite complex in itself a technique of this type of treatment and requires special equipment, experience, and qualifications of the surgeon's. This in turn explains the high costs associated with this treatment method.

There is a method of treatment of causalgia (Great medical encyclopedia - volume 10 - Boars - Koali the th of which is the use of analgesics, sedative drugs, physical therapy and psychotherapy.

The disadvantages of this method are: the need for or availability of relevant groups of drugs, their high cost, existing contraindications to their use and potential side effects. The need for specialized psychotherapeutic services.

Objective of the claimed invention is to increase the efficiency of the treatment and rehabilitation of patients suffering from causalgia.

This object is achieved in that according to the method of treatment of causalgia after amputation of the lower extremities, including the use of physiotherapeutic procedures, intraarterially injected hydrogen peroxide solution concentration of 0.1-0.15%.

The advantages of this method are the simplicity of the methodology, low invasiveness and trauma (compared with operative treatment), efficiency, availability, low cost, no need for specific skills of the doctor and his qualifications. In addition, the absence of contraindications and hypoallergenic.

The method is as follows. For intraarterial administration used the ora of hydrogen peroxide at physiological salt solution. Puncture of the femoral artery is performed by a standard method. After careful processing, the groin alcohol, punctured femoral artery intramuscular needle just below the inguinal ligament in the typical place. The rate of injection should not exceed 14-15 ml per minute. You can enter up to 200.0 ml of solution. The number of sessions varies from 3 to 10. The sessions are held daily or every other day. When expressed pain syndrome may 2-fold introduction to the day.

Patient L., 46 years old. Diagnosis: Cellulitis region of the right knee joint. The stump of both lower extremities at the level of the lower third of the leg. Causalgia. The patient underwent intraarterial introduction 0.12% solution of hydrogen peroxide in a volume of 200.0 ml in the left and right femoral arteries daily for 5 days. Achieved complete relief of kaupallisesti pain. Observed within 6 months, the pain didn't bother.

Patient, 56 years. Diagnosis: Cellulitis of the left foot against the background of osteomyelitis Plusnin bones. Diabetes mellitus type II, II severity. In a patient after amputation on the main disease left lower extremity at the level of the lower third of the leg there is a strong kaupallisessa pain. Performed nutrire 10 days. Achieved a pronounced analgesic effect. The patient was discharged, observed within 1.5 months and the pain is not worried.

A method for the treatment of causalgia after amputation of the lower extremities, including the introduction of medicines, characterized in that as a drug used by 0.1 to 0.15% solution of hydrogen peroxide in a volume of 200.0 ml, which is introduced into the femoral artery.

 

Same patents:
The invention relates to medicine, in particular to the venereal diseases, urology and gynecology

The invention relates to medicine, toxicology, and can be used as an antidote the remedy for intoxication by heavy metals
The invention relates to experimental medicine and can be used to prevent intra-abdominal adhesion experiment
The invention relates to the field of cosmetics, namely, cosmetic, cream against pain and mastitis

The invention relates to nucleoside analogs of formula (1) in which R1represents H or a group protecting the hydroxyl, R2represents H, a group protecting the hydroxyl group of phosphoric acid, a protected group, phosphoric acid or a group of the formula P(R3R4in which R3and R4are the same or different and represent a hydroxyl group, a protected hydroxyl group, alkoxygroup, allylthiourea, cyanoacetylurea, amino group, substituted alkyl group; And represents alkylenes group containing from 1 to 4 carbon atoms, and a represents a substituted purine-9-ilen group or substituted 2-oxopyrimidine-1-ilen group containing at least one Deputy, selected from hydroxyl groups, protected hydroxyl groups, amino groups, protected amino groups, alkyl groups

The invention relates to medicine and pharmacology, specifically to immunology

The invention relates to medicine, in particular neurology and venereology, and for the treatment of syphilis vasculitis

The invention relates to pharmacy and medicine and relates to the development of new medicines

The invention relates to medicine, to afferent therapy, and can be used to treat hepatorenal syndrome in patients with decompensated liver cirrhosis complicated by ascites syndrome

The invention relates to indole derivative of General formula I:

where R1represents hydrogen, halogen, methoxy; R2represents hydrogen, halogen, methyl, ethyl, methoxy; R3represents carboxy, tetrazolyl or CONHSO2R4in which R4represents methyl, ethyl, phenyl, 2,5-dimethylisoxazole, trifluoromethyl; T represents-CH2- or-SO2-; and ring a is 3-chlorophenyl, 4-chlorophenyl, 3-triptoreline, 3,4-dichlorophenyl, 3,4-differenl, 3-fluoro-4-chlorophenyl, 3-chloro-4-forfinal, 2,3-dichloride-5-yl; or their pharmaceutically acceptable salts or esters, as well as pharmaceutical compositions containing them
The invention relates to medicine, in particular to pulmonology and concerns of conservative stopping pulmonary hemorrhage

The invention relates to palletization derived bacteriochlorophyll formula I, I' or I"

where a is a HE, OR1, -O-(CH2)n-Y, -S-(CH2)n-Y, -NH-(CH2)n-Y, -O-(CH2)2-OH, -NH-(CH2)2-NH-BOC, or-N(CH2-CH=CH2)2where R1represents Na+, K+, (CA2+)0,5, (Mg2+)0,5Li+, NH+4,+NH3-C(CH2OH)3,+NH3-CH2-(CHOH)4-CH2OH,+NH2(CH3)-CH2(SNON)4-CH2OH, or+N(Cn'H2n'+1)4; R2represents N or C1-C12the alkyl for the compounds of formula I', and R2represents H, HE or COOR4for the compounds of formula I, where R4represents C1-C12alkyl or C3-C12cycloalkyl; R3represents N or C1-C12the alkyl for the compounds of formula I', and R3represents H, HE, or C1-C12alkyl or alkoxy with the R'3X-where R'1, R'2and R'3each independently represents-CH3or-C2H5; X represents F, Cl, Br or I, n is 1, 2, 3 or 4, and where * denotes an asymmetric carbon atom and --- represents a single saturated bond or an unsaturated double bond pharmaceutical composition having a capacity of detection or treatment of tumors containing at least one compound of formula I, I' or I", three methods for obtaining the compounds of formula I

The invention relates to the pharmaceutical industry and relates to anti-inflammatory drugs for external use

The invention relates to compounds of General formula I:

where n is 1, 2 or 3; R1and R2independently selected from hydrogen and alkyl; R3represents alkyl; R4-R7independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkylthio, aaltio, alkylsulfonyl, alkylsulfonyl, arysulfatase, arylsulfonyl, amino, monoalkylamines, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarboxylic, arylcarbamoyl, aminocarbonyl, monoalkylammonium, dialkylaminoalkyl, alkoxycarbonyl, aminocarbonyl, monoalkylammonium, dialkylaminoalkyl, monoalkylammonium, dialkylaminomethyl, or R5and R6together form a carbocyclic or heterocyclic ring, its pharmaceutically acceptable salts and prodrugs and a method of treatment and pharmaceutical compositions having the properties of agonist 5-HT2

The invention relates to a new group of pyrrole, in particular 1-(2,4,6-trimetilfenil)-2-[(2-hydroxy-3-phenyloxy)-N-substituted-aminomethyl]pyrrole General formula

where VI, R=-H, VIa R=-C(O)H, VIIŠ± R=-C(O)CH3, VIIIa R=-CH3, VIIIŠ± R=-C2H5and their pharmaceutically acceptable salts of dicarboxylic acids, which have anti-arrhythmic and anti-ischemic activity and intensity of effect exceeds applicable in the clinic verapamil, amiodarone and lidocaine
The invention relates to chemistry and medicine

The invention relates to omega-Amida N-arylsulfonamides formula I

and/or stereoisomeric forms of the compounds I and/or physiologically acceptable salts of the compounds I where R1means phenyl, phenyl, substituted once with halogen, the rest of the heterocycle of the following groups: morpholine, pyrrolidine; R2means N; R3means -(C1-C4)-alkyl-C(O)-N(R6)-R7where R6and R7together with the nitrogen to which they are bound, form a residue of formula IIa, IIe

moreover, in formula IIa, IIe q indicates an integer of zero or 1, Z denotes the carbon atom or a covalent bond, and R8means a hydrogen atom or halogen, or R3means -(C1-C4)-alkyl-C(O)-Y, where Y means the remainder of the formula IIC or IId

moreover, in formulas IIc and IId, R8means H or halogen, R9means H, or R3means -(C1-C4)-alkyl-C(O)-N(R9)-(CH2)about-N(R4)-R5and R9has the above values, means the integer 2 and R is substituted by-O-, And means covalent bond, B means -(CH2)m- where m is zero, X is-CH=CH-

Immunosuppressant // 2228178
The invention relates to new biologically active substances from the class alkenylboronic acids and can be used in medicine and biology as the basis for development of medicinal products
The invention relates to medicine and can be used in surgery, orthopedics and traumatology
Up!